Amgen 2015 Annual Report Download - page 52

Download and view the complete annual report

Please find page 52 of the 2015 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 132

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132

44
submitted a BLA to the FDA for Retacrit™, a proposed biosimilar to EPOGEN®. For discussion of ongoing litigation between us
and Hospira, see Part IV—Note 18, Contingencies and commitments, to the Consolidated Financial Statements.
Sensipar®/Mimpara®
Total Sensipar®/Mimpara® sales by geographic region were as follows (dollar amounts in millions):
Year ended
December 31,
Year ended
December 31,
Year ended
December 31,
2015 Change 2014 Change 2013
Sensipar® — U.S. $ 1,069 34 % $ 796 5% $ 757
Sensipar®/Mimpara® — ROW 346 (4)% 362 9% 332
Total Sensipar®/Mimpara®$ 1,415 22 % $ 1,158 6% $ 1,089
The increase in global Sensipar®/Mimpara® sales for 2015 was driven primarily by unit demand growth and an increase in
net selling price in the United States. ROW Sensipar®/Mimpara® sales were negatively impacted by changes in foreign currency
exchange rates.
The increase in global Sensipar®/Mimpara® sales for 2014 was driven primarily by unit demand growth and an increase in
net selling price in the United States, offset partially by unfavorable changes in U.S. wholesaler and, based on prescription data,
end-user inventories.
XGEVA®
Total XGEVA® sales by geographic region were as follows (dollar amounts in millions):
Year ended
December 31,
Year ended
December 31,
Year ended
December 31,
2015 Change 2014 Change 2013
XGEVA® — U.S. $ 1,006 17% $ 857 12% $ 764
XGEVA® — ROW 399 10% 364 43% 255
Total XGEVA®$ 1,405 15% $ 1,221 20% $ 1,019
The increases in global XGEVA® sales for 2015 and 2014 were driven primarily by unit demand growth.
Prolia®
Total Prolia® sales by geographic region were as follows (dollar amounts in millions):
Year ended
December 31,
Year ended
December 31,
Year ended
December 31,
2015 Change 2014 Change 2013
Prolia® — U.S. $ 837 34% $ 625 35% $ 462
Prolia® — ROW 475 17% 405 44% 282
Total Prolia®$ 1,312 27% $ 1,030 38% $ 744
The increases in global Prolia® sales for 2015 and 2014 were driven primarily by unit demand growth.
NEUPOGEN®
Total NEUPOGEN® sales by geographic region were as follows (dollar amounts in millions):
Year ended
December 31,
Year ended
December 31,
Year ended
December 31,
2015 Change 2014 Change 2013
NEUPOGEN® — U.S. $ 793 (5)% $ 839 (28)% $ 1,169
NEUPOGEN® — ROW 256 (20)% 320 40 % 229
Total NEUPOGEN®$ 1,049 (9)% $ 1,159 (17)% $ 1,398